Armen Shanafelt

Armen Shanafelt

Presidente en
Abshanafelt Advisory
.
66 años
Health Technology
Consumer Services
Finance

Perfil

Armen Shanafelt brings over 29 years of operational experience in the pharmaceutical, biotechnology, and diagnostic businesses to Lilly Ventures.
Previous to joining Lilly Ventures in 2009, Armen held leadership and executive positions in the R&D organizations of DNAX Research Institute, Bayer Pharmaceuticals, Roche Diagnostics, and Eli Lilly and Company.
Armen currently serves as a director on the boards of Aeglea BioTherapeutics (NASDAQ: AGLE), Aileron Therapeutics (NASDAQ: ALRN), Protagonist Therapeutics (NASDAQ: PTGX), Surface Oncology (NASDAQ: SURF), Sutro Biopharma and Symic Biomedical.
He is a Kauffman Fellow (Class 14).
Armen received his B.S.
Degree in Chemistry and Physics from Pacific Lutheran University, and his Ph.D.
in Chemistry from the University of California, Berkeley.

Cargos activos de Armen Shanafelt

EmpresasCargoInicio
Abshanafelt Advisory
Presidente 01/01/2021

Antiguos cargos conocidos de Armen Shanafelt.

EmpresasCargoFin
SURFACE ONCOLOGY, INC. Director/Miembro de la Junta 08/09/2023
SPYRE THERAPEUTICS, INC. Presidente 01/01/2019
Inversor de Capital Privado 01/12/2020
REIN THERAPEUTICS INC. Director/Miembro de la Junta 19/06/2019
Director/Miembro de la Junta 01/06/2019
Ver el detalle de la experiencia de Armen Shanafelt.

Formación de Armen Shanafelt.

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Relaciones

60

Relaciones de 1er grado

17

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Empresas relacionadas

Empresas privadas17

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Consumer Services

Consumer Services

Health Technology

Technology Services

Health Technology

Health Technology

Abshanafelt Advisory